Stock Research for BEAM

BEAM

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BEAM Stock Chart & Research Data

The BEAM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BEAM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BEAM Due diligence Resources & Stock Charts

The BEAM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BEAM Detailed Price Forecast - CNN Money CNN View BEAM Detailed Summary - Google Finance
Yahoo View BEAM Detailed Summary - Yahoo! Finance Zacks View BEAM Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BEAM Trends & Analysis - Trade-Ideas Barrons View BEAM Major Holders - Barrons
NASDAQ View BEAM Call Transcripts - NASDAQ Seeking View BEAM Breaking News & Analysis - Seeking Alpha
Spotlight View BEAM Annual Report - CompanySpotlight.com OTC Report View BEAM OTC Short Report - OTCShortReport.com
TradeKing View BEAM Fundamentals - TradeKing Charts View BEAM SEC Filings - Bar Chart
WSJ View Historical Prices for BEAM - The WSJ Morningstar View Performance/Total Return for BEAM - Morningstar
MarketWatch View the Analyst Estimates for BEAM - MarketWatch CNBC View the Earnings History for BEAM - CNBC
StockMarketWatch View the BEAM Earnings - StockMarketWatch MacroAxis View BEAM Buy or Sell Recommendations - MacroAxis
Bullish View the BEAM Bullish Patterns - American Bulls Short Pains View BEAM Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BEAM Stock Mentions - StockTwits PennyStocks View BEAM Stock Mentions - PennyStockTweets
Twitter View BEAM Stock Mentions - Twitter Invest Hub View BEAM Investment Forum News - Investor Hub
Yahoo View BEAM Stock Mentions - Yahoo! Message Board Seeking Alpha View BEAM Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BEAM - SECform4.com Insider Cow View Insider Transactions for BEAM - Insider Cow
CNBC View BEAM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BEAM - OTC Markets
Yahoo View Insider Transactions for BEAM - Yahoo! Finance NASDAQ View Institutional Holdings for BEAM - NASDAQ


Stock Charts

FinViz View BEAM Stock Insight & Charts - FinViz.com StockCharts View BEAM Investment Charts - StockCharts.com
BarChart View BEAM Stock Overview & Charts - BarChart Trading View View BEAM User Generated Charts - Trading View




Latest Financial News for BEAM


Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans
Posted on Thursday April 11, 2024

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...


Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Posted on Thursday March 28, 2024

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Posted on Tuesday March 26, 2024

Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the clearance of its clinical trial authorisation (CTA) application by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency for BEAM-302, an in vivo base editor, as a potential treatment for patients with


Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Posted on Friday March 01, 2024

As you might know, Beam Therapeutics Inc. ( NASDAQ:BEAM ) just kicked off its latest annual results with some very...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.